Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$29.14 USD

29.14
16,916,194

+0.17 (0.59%)

Updated Sep 27, 2024 03:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Amgen's Blincyto Gets Positive CHMP Opinion for Line Extension

Amgen's (AMGN) leukemia drug, Blincyto receives positive CHMP opinion for label expansion to include minimal residual disease.

Drug Pricing Resurfaces, Pfizer to Raise Cost of 41 Drugs

Per a Wall Street report, Pfizer (PFE) plans to increase the list prices of its 41 prescription drugs in 2019.

The Zacks Analyst Blog Highlights: Pfizer, Cisco, Southern, SunTrust Banks and AmerisourceBergen

The Zacks Analyst Blog Highlights: Pfizer, Cisco, Southern, SunTrust Banks and AmerisourceBergen

uniQure Up on Positive Data From Mid-Stage Hemophilia Study

uniQure's (QURE) gene therapy candidate, AMT-061, demonstrates significant improvement in hemophilia B patients in a mid-stage study. Investors' sentiment improves.

Mark Vickery headshot

Top Research Reports for Pfizer, Cisco & Southern Company

Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Cisco (CSCO) and Southern Company (SO).

Lilly Offers Updates on Progress of Headache Disorder Drugs

Eli Lilly (LLY) files NDA with FDA for migraine candidate, lasmiditan. FDA grants Breakthrough Therapy status to Emgality for episodic cluster headache indication.

Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes

Sangamo Therapeutics (SGMO) postpones data presentation from its haemophilia study, following dose escalation recommendation from an independent committee. This raises concerns about its development.

Shire's Filing Accepted by FDA for Gattex's Label Expansion

The FDA accepts Shire's (SHPG) sNDA and is expected to take action in March 2019.

Pfizer (PFE) Stock Moves -0.38%: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $44.11, marking a -0.38% move from the previous day.

Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug

Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.

Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction

Aerie's (AERI) Q3 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up

Nektar's (NKTR) earnings and sales beat estimates in the third quarter. The company enters oncology clinical collaboration with Pfizer to evaluate NKTR-214 combination therapy.

Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review

Sanofi (SNY) and partner Regeneron announce priority review to label expansion application of Dupixent seeking approval in adolescent patients with moderate-to-severe atopic dermatitis.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

Pfizer (PFE) closed the most recent trading day at $42.99, moving -1.22% from the previous trading session.

Neena Mishra headshot

Can Low Volatility ETFs Protect Your Portfolio?

Low volatility ETFs are designed to perform well in a volatile market environment, here is what investors need to know.

Sweta Killa headshot

Beaten-Down Pharma ETFs to Buy Post Q3 Results

Despite strong results, the broad market sell-off took the sheen from the pharma ETFs over the past month. These funds have a Zacks ETF Rank #2 (Buy), suggesting solid entry point on beaten down prices.

Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates

Corcept (CORT) reports in-line earnings in the third quarter of 2018 and reaffirms its revenue guidance for 2018.

Exelixis (EXEL) Q3 Earnings, Revenues Beat on Cabometyx Sales

Exelixis's (EXEL) earnings and revenue beat expectations in the third-quarter propelled by strong sales of Cabometyx.

Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates

Conatus (CNAT) incurs in-line loss for the third quarter of 2018. Sales miss estimates.

Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO

We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.

Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus

Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.

Swarup Gupta headshot

Dow 30 Stock Roundup: Apple, Coca-Cola, DowDuPont Earnings Impress

The index experienced one of its better weeks in recent times, buoyed by strong earnings and hopes of a resolution to trade tensions.

Ryan McQueeney headshot

Pfizer and Coca-Cola Earnings Help Safer Income Stocks Shine

After a volatile October, Ryan McQueeney highlights two income companies that fared better than the broader markets during the selloff---Pfizer and Coca-Cola---and explains why earnings and defensive posturing might have helped the stocks.

PFE vs. NVO: Which Stock Should Value Investors Buy Now?

PFE vs. NVO: Which Stock Is the Better Value Option?

PFE vs. NVO: Which Stock Is the Better Value Option?

PFE vs. NVO: Which Stock Is the Better Value Option?